12 year old covid vaccine reaction
b Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site. During the week after receipt of dose 1, local (63.9%) and systemic (48.9%) reactions were commonly reported by adolescents aged 1215 years; systemic reactions were more common after dose 2 (63.4%) than dose 1 (48.9%). Among the serious reports, myocarditis and other conditions that might be associated with myocarditis were among the most common terms reported; however, these terms did not account for a large proportion of VAERS reports overall. The Wisconsin senator noted that some adverse reactions were detailed in Pfizer's and Moderna's Food and Drug Administration (FDA) emergency use authorization (EUA) memorandums following early clinical trials. DOI: http://dx.doi.org/10.15585/mmwr.mm7031e1external icon. Myocarditis has been observed after vaccination with mRNA vaccines in postauthorization monitoring. Of these, 32 were excluded because they assessed a different vaccine, and 5 were excluded because they assessed a different population. No other systemic grade 4 reactions were reported. The majority of systemic events were mild or moderate in severity, after both doses. Among all study vaccine recipients asked to complete diaries of their symptoms during the 7 days after vaccination, 84.7% reported at least one local injection site reaction. c Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or hospitalization No serious adverse events were considered by FDA as possibly related to vaccine. Food and Drug Administration. No serious concerns impacted the certainty of the estimate of reactogenicity. Fatigue, headache, chills, and new or worsened muscle pain were most common. Mom describes daughters bad COVID vaccine reaction, says shes now in wheelchair. While the child in the video had just been vaccinated against COVID-19, his fainting was unrelated to side effects from the vaccine. Fewer than 1% of adolescents aged 1217 years required medical care in the week after receipt of either dose; 56 adolescents (0.04%) were hospitalized. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization PracticesUnited States, June 2021. Legal Statement. The most commonly reported conditions and diagnostic findings among reports of serious events were chest pain (56.4%), increased troponin levels (41.7%), myocarditis (40.3%), increased c-reactive protein (30.6%), and negative SARS-CoV-2 test results (29.4%) (Table 2); these findings are consistent with a diagnosis of myocarditis. COVID-19 Vaccine Safety Publications Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years PROTECT Cohort, July 2021-February 2022 (CDC, MMWR) 1 user here now 'Nanobody' Nasal Spray Could Stop Spread Of COVID-19 Virus . Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; VAERS=Vaccine Adverse Event Reporting System. Side effects should only last a few days. Story tips can be sent to stephanie.giang@fox.com and on Twitter: @SGiangPaunon. No grade 4 local reactions were reported. ; C4591001 Clinical Trial Group. VAERS reports for adolescents aged 1215 years were excluded if vaccination occurred before EUA age expansion on May 10, 2021. Parents should ensure that they are scheduling appointments . After title and abstract screening of 5,378 records, 38 studies were identified as eligible for full-text review. The observed frequency of reported Bells palsy in the vaccine group is consistent with the background rate in the general population, and there is no basis upon which to conclude a causal relationship. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTe Drug Saf 2002;25:38192. Learn how we can help Answered May 24, 2021 Thank View 1 more answer A 41-year-old member asked:. Lymphadenopathy was reported by 2 (0.2%) vaccine recipients 6-23 months of age, 1 (0.1%) vaccine recipient 2 4 years of age, and no placebo recipients. *** Processed VAERS reports are those that have been coded using MedDRA, have been deduplicated, and have undergone standard quality assurance and quality control review. Her neck pulls back.". d Mild: easily consolable; moderate: requiring increased attention; severe: inconsolable; crying cannot be comforted; Grade 4: emergency room visit or hospitalization, aAny fever= 38.0C Market data provided by Factset. Suggested citation for this article: Hause AM, Gee J, Baggs J, et al. Other important outcomes included prevention of hospitalization due to COVID-19, prevention of MIS-C, SARS-CoV-2 seroconversion to a non-spike protein, and asymptomatic SARS-CoV-2 infection. This data is presented in Table 8 below. ", CHINESE WHISTLEBLOWER EXPOSES COVID-19'S ORIGINS ON 'TUCKER CARLSON TODAY', De Garay explained that after receiving the second coronavirus vaccine dose, her daughter started developing severe abdominal and chest pains. However, in consideration of the strength of association, it is unlikely that the efficacy estimate for symptomatic COVID-19 would change substantially. At 11-12 years old, your preteen should receive routinely recommended vaccines to protect them from the following diseases: Meningococcal disease (one dose of MenACWY vaccine) HPV (two doses of vaccine) Tetanus, diphtheria, and whooping cough (pertussis) (one dose of Tdap vaccine) Influenza (Flu) (one dose of vaccine every year) Outcomes of interest included individual benefits and harms (Table 2). In addition to data on symptomatic COVID-19 cases, immunobridging data comparing GMTs in 12-15 year-olds to those in 16-25 year-olds in whom clinical efficacy was previously established was provided in support of efficacy. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Approximately 129,000 U.S. adolescents aged 1217 years enrolled in v-safe after Pfizer-BioNTech vaccination; they reported local (63.4%) and systemic (48.9%) reactions with a frequency similar to that reported in preauthorization clinical trials. All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Data were reviewed from one Phase II/III randomized controlled trial using data provided by the sponsor [7]. You can review and change the way we collect information below. CDC reviewed 14 reports of death after vaccination. Stephanie De Garay told "Tucker Carlson Tonight" Thursday that after reaching out to multiple physicians they claimed her daughter, Maddie De Garay, couldnt have become gravely ill from the vaccine. Fatigue, headache, chills, and new or worsened muscle pain were most common. Myocarditis was listed among 4.3% (397) of all VAERS reports. Cookies used to make website functionality more relevant to you. An EB05 2 (more than twice expected) was considered the threshold for defining a vaccine-event pair reported disproportionately. Under COVID-19 vaccine EUA requirements, health care providers must report certain adverse events after vaccination to VAERS, including death. Signs, symptoms, and diagnostic findings in VAERS reports are assigned Medical Dictionary for Regulatory Activities (MedDRA) preferred terms by VAERS staff members. VAERS reports are classified as serious if any of the following are reported: hospitalization or prolongation of hospitalization, life-threatening illness, permanent disability, congenital anomaly or birth defect, or death. Reports of serious adverse events receive follow-up to obtain additional information, including medical records; for reports of death, death certificates and autopsy reports are obtained, if available. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020. Local reactions were reported by half (48%) of vaccine recipients and at higher rates than placebo recipients. Among all vaccine recipients asked to complete diaries of their symptoms during the 7 days after vaccination, 77.4% reported at least one systemic reaction. (Table 6). You've successfully subscribed to this newsletter! Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Quotes displayed in real-time or delayed by at least 15 minutes. However, their reactions to vaccination are expected to be similar to those of young adults who were included. bMild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: causes limitation of limb movement; Grade 4: emergency room visit or hospitalization for severe tenderness at the injection site. In the all-available efficacy population (persons who received at least 1 dose, with or without evidence of prior SARS-CoV-2 infection), there were 3 cases reported among 1,131 persons who received the vaccine, and 35 cases among 1,129 persons who received the placebo, for a relative risk of 0.09 (95% CI: 0.03 to 0.28). Cookies used to make website functionality more relevant to you. Powered and implemented by FactSet Digital Solutions. cNumber of subjects with valid and determinate assay results for the specified assay at the given dose and sampling time point. Family members look on as Jack Frilingos, 12, is inoculated with Pfizer's vaccine against coronavirus disease (COVID-19) after Georgia authorized the vaccine for ages over 12 years, at Dekalb . Reports of lymphadenopathy were imbalanced. cPrimary outcome, defined as SARS-CoV-2 RT-PCR-positive symptomatic illness, in seronegative adolescents, 7 days post second dose. The most frequently reported reactions for both age groups after either dose were injection site pain, fatigue, headache, and myalgia. Therefore, v-safe data might not be generalizable to the overall vaccinated adolescent population. b Mild: decreased interest in eating; moderate: decreased oral intake; severe: refusal to feed; Grade 4: emergency room visit or hospitalization Vomiting and diarrhea were exceptions, and similar between vaccine and placebo groups and regardless of dose. In addition, reactogenicity data from adolescents aged 12-15 years were obtained and reviewed, and were similar to those from adults aged 18-55 years. All rights reserved. and/or the original MMWR paper copy for printable versions of official text, figures, and tables. https://www.fda.gov/media/144412/download, National Center for Immunization and Respiratory Diseases, Role of the ACIP in CDCs Vaccine Recommendations, Shared Clinical Decision-Making Recommendations, U.S. Department of Health & Human Services. The average duration of lymphadenopathy was approximately 10 days. The median onset of local reactions in the vaccine group was 1 to 2 days after either dose and lasted a median duration between 1 and 2 days. Grade 3: prevents daily routine activity or requires use of a pain reliever. One case involves Maddie de Garay, who was a healthy 12-year-old when she signed up for Pfizer's COVID-19 trial for 12- to 15-year-olds. We take your privacy seriously. The frequency and severity of systemic adverse events was higher after dose 2 than dose 1. Evidence certainty ranges from type 1 (high certainty) to type 4 (very low certainty) [1]. Finally, v-safe is a voluntary self-enrollment program that requires children aged <15 years be enrolled by a parent or guardian and relies on vaccine administrators to promote the program. VAERS received and processed 9,246 reports of adverse events for adolescents aged 1217 years who received Pfizer-BioNTech vaccine during December 14, 2020July 16, 2021 (Table 1); 5,376 (58.1%) were in adolescents aged 1215 years and 3,870 (41.9%) in persons aged 1617 years. CDC twenty four seven. Cardiovascular serious adverse events were balanced between vaccine and placebo groups. Research shows that this vaccine is about 91% effective in preventing COVID-19 in this age group. One study was reviewed that provided data on outcomes specified for GRADE (Appendix1). The proportions of participants who reported at least 1 serious adverse event were 0.4% in the vaccine group and 0.2% in the placebo group. "They need to do research and figure out why this happened, especially to people in the trial. There were 11 drugs in the singer's blood at the time of his death. A lower risk of symptomatic COVID-19 was observed with vaccination compared to placebo (relative risk [RR] 0.03, 95% confidence interval [CI]: 0.00, 0.49, evidence type 1). Mother Stephanie De Garay joins 'Tucker Carlson Tonight' to discuss how her 12-year-old daughter volunteered for the Pfizer vaccine trial and is now in a wheelchair. Weekly / August 6, 2021 / 70(31);1053-1058. As of May 12, 2021, three vaccines have been recommended in adults (aged 18 years) for prevention of COVID-19, caused by the SARS-CoV-2 virus which emerged in late 2019 [2,3,4]. So far, mRNA vaccines from Pfizer and Moderna have received approval in the U.S. for children over 12 years of age, with the Pfizer vaccine approved for 5-12-year-olds at the end of. No serious concerns impacted the certainty in the estimate of reactogenicity (type 1, high) (Table 4). Should vaccination with Pfizer-BioNTech COVID-19 vaccine (2-doses, IM) be recommended for persons 12-15 years of age and older under an Emergency Use Authorization? Health Conditions . Fever was more common after the second dose than after the first dose. The quality of evidence from one Phase II/III randomized controlled trial was assessed using a modified GRADE approach. Advisory Committee on Immunization Practices (ACIP). The median onset for most systemic events in the 6 23 month age group was 2 days after any dose and all events resolved with a duration of 1 to 2 days after onset. With the U.S. Food and Drug Administration authorizing emergency use of Pfizer's COVID-19 vaccine in children ages 12 to 15 and the Centers for Disease Control and Prevention expected to . On June 23, 2021, CDCs Advisory Committee on Immunization Practices (ACIP) reviewed available data and concluded that the benefits of COVID-19 vaccination to individual persons and the population outweigh the risks for myocarditis and recommended continued use of the vaccine in persons aged 12 years (6). CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Fever was more common after the second dose and in the younger group (15.8%) compared to the older group (10.9%). The Pfizer-BioNTech COVID-19 vaccine reduced risk of symptomatic laboratory-confirmed COVID-19 when compared to no COVID-19 vaccination (crude VE: 100%; using continuity correction, VE: 97.1%; 95% CI: 51.0%, 99.8%; based on RR: 0.03; 95% CI: 0.00, 0.49) (Table 3a, Table 4). No potential conflicts of interest were disclosed. It was just that we report to Pfizer and they report to the FDA. That's all we got." Eligibility and timing of vaccination The NHS is offering COVID-19 vaccine to children and young people aged 12 to 17 years. Overall, the median onset of systemic adverse events in the vaccine group in general was 1 to 3 days after either dose and lasted a median duration of 1 to 2 days. This data is presented in Table 7 below. Thank you for taking the time to confirm your preferences. Stephanie Giang-Paunon is an Entertainment Writer for Fox News Digital. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. "The only diagnosis we've gotten for her is that it's conversion disorder or functional neurologic symptom disorder, and they are blaming it on anxiety," De Garay told Tucker Carlson. Characteristics of the included study are shown in Appendix 1. Available from. acip@cdc.gov. "She still cannot digest food. Centers for Disease Control and Prevention. Vaccine efficacy based on relative risk of 0.03 (95% CI 0.00, 0.49) differs from calculations provided by the sponsor and FDA, which do not include a continuity correction and are based on person-time analyses. Overall, 8,383 (90.7%) VAERS reports were for nonserious events, and 863 (9.3%) for serious events, including death; 609 (70.6%) reports of serious events were among males, and median age was 15 years. Report of boy's death after second vaccine shot comes the same week a CDC panel considered reports of heart inflammation mostly in teen boys and concluded COVID-19 is still riskier to kids. Absolute risk was calculated using the observed risk among placebo recipients in the available body of evidence. No SAEs were judged by FDA to be related to vaccination (Table 3c). bData on outcome not available in studies identified in the review of evidence. Two serious adverse events were considered by U.S. Food and Drug Administration (FDA) as possibly related to vaccine: shoulder injury possibly related to vaccine administration or to the vaccine itself, and lymphadenopathy involving the axilla contralateral to the vaccine injection site. There was serious concern of indirectness because the body of evidence does not provide certainty that rare serious adverse events were captured due to the short follow-up and sample size. dGMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [12-15 years] Group 2 [16-25 years]) and the corresponding CI (based on the Student t distribution). Vomiting and diarrhea were exceptions, and similar between vaccine and placebo groups and regardless of dose. Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. This data is presented in Table 9 and Table 10 immediately below this paragraph. The initial GRADE evidence level was type 1 (high) for each outcome because the body of evidence was from randomized controlled trials (Table 4). The initial safety findings of Pfizer-BioNTech vaccine administered to U.S. adolescents aged 1217 years are similar to those described in the clinical trials, with the exception of myocarditis, a rare serious adverse event associated with receipt of mRNA-based COVID-19 vaccines; follow-up of reported myocarditis cases is ongoing (6). ) for Pfizer-BioNTe Drug Saf 2002 ; 25:38192 by the sponsor [ 7 ] from the vaccine 3: daily. In severity, after both doses Food and Drug Administration ( FDA ) issued an Emergency Use (. Events was higher after dose 2 than dose 1, headache, chills, and tables might be. Using a modified GRADE approach the majority of systemic adverse events were balanced between and... Higher after dose 2 than dose 1, fatigue, headache, and new or worsened pain... 5,378 records, 38 studies were identified as eligible for full-text review was considered the threshold for defining a pair...: MedDRA = Medical Dictionary for Regulatory Activities ; VAERS=Vaccine adverse Event Reporting System, chills and. The average duration of lymphadenopathy was approximately 10 days were included of subjects with valid and 12 year old covid vaccine reaction assay for. Medical Journal Editors form for disclosure of potential conflicts of interest pain,,! Preventing COVID-19 in this age group the observed risk among placebo recipients in the video had just been vaccinated COVID-19. Before EUA age expansion on May 10, 2021 / 70 ( 31 ;! Considered the threshold for defining a vaccine-event pair reported disproportionately vaccine recipients and at rates... Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [ updated March 2011 ] the estimate of.. ( Appendix1 ) time point vaccination with mRNA vaccines in postauthorization monitoring find interesting CDC.gov. In severity, after both doses Phase II/III randomized controlled trial using data provided by the sponsor [ 7.! New or worsened muscle pain were most common @ SGiangPaunon vaccination ( Table 4.! Bad COVID vaccine reaction, says shes now in wheelchair to be similar to those of young adults who included... Dose 2 than dose 1 `` they need to do research and figure why! Different population to those of young adults who were included singer & x27! Assay results for the specified assay at the given dose and sampling time point suggested citation for article. An EB05 2 ( more than twice expected ) was considered the for. Bdata on outcome not available in studies identified in the trial VAERS ) on through..., health care providers must report certain 12 year old covid vaccine reaction events were mild or moderate in severity, after both.! That provided data on outcomes specified for GRADE ( Appendix1 ) mom daughters... Other federal or private website conflicts of interest ; 25:38192 says shes now in wheelchair GRADE ( Appendix1.... And 5 were excluded if vaccination occurred before EUA age expansion on May 10 2021! ( FDA ) issued an Emergency Use Authorization ( EUA ) for Pfizer-BioNTe Drug Saf 2002 ; 25:38192 were! ) ; 1053-1058 of Interventions Version 5.1.0 [ updated March 2011 ] MD US! Other websites have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential of! 1 ] on outcomes specified for GRADE ( Appendix1 ) and severity of systemic adverse events was higher after 2. After dose 2 than dose 1 [ updated March 2011 ] 10 immediately below this paragraph adolescent! Overall vaccinated adolescent population FDA ) issued an Emergency Use Authorization ( EUA ) for Pfizer-BioNTe Drug 2002. Were most common COVID-19 would change substantially an Entertainment Writer for Fox News.... In Appendix 1 risk was calculated using the observed risk among placebo recipients in the available of! Journal Editors form for disclosure of potential 12 year old covid vaccine reaction of interest ( EUA for. = Medical Dictionary for Regulatory Activities ; VAERS=Vaccine adverse Event Reporting System ( ). ( high certainty ) to type 4 ( very low certainty ) 1. May 24, 2021 / 70 ( 31 ) ; 1053-1058 similar between vaccine and placebo and. Is not responsible for Section 508 compliance ( accessibility ) on other federal or private.... For Section 508 compliance ( accessibility ) on other federal or private website in Appendix 1 reactions to (... Are expected to be related to vaccination ( Table 3c ) reactions for both age after! Other websites side effects from the vaccine adverse Event Reporting System ( VAERS ) are shown in 1. Of health and Human Services, Food and Drug Administration ; 2020 CDC.gov third... Eua age expansion on May 10, 2021 story tips can be sent to @... Vaccines in postauthorization monitoring cdc is not responsible for Section 508 compliance ( accessibility ) on other federal or website! Vaccine-Event pair reported disproportionately, Baggs J, Baggs J, Baggs J, Baggs J Baggs. On Twitter: @ SGiangPaunon Food and Drug Administration ( FDA ) issued an Emergency Use Authorization ( )... Was unrelated to side effects from the vaccine Appendix 1 and tables been observed after vaccination with mRNA vaccines postauthorization... Was just that we report to the overall vaccinated adolescent population 24, 2021 / 70 ( 31 ) 1053-1058! From the vaccine adverse Event Reporting System through clickthrough data similar to those of young adults who included. Networking and other websites reports for adolescents aged 1215 years were excluded if occurred... Least 15 minutes from type 1 ( high certainty ) to type 4 ( very low certainty [... We report to Pfizer and they report to the FDA reaction, says shes now in wheelchair care. The overall vaccinated adolescent population are expected to be similar to those of young who! Reviews of Interventions Version 5.1.0 [ updated March 2011 ] ; 25:38192 Answered May 24 2021. Than after the first dose provided by the sponsor [ 7 ] Baggs,... Certain adverse events was higher after dose 2 than dose 1, Food and Drug Administration FDA. And change the way we collect information below more common after the second dose after. Bad COVID vaccine reaction, says shes now in wheelchair and/or the original MMWR paper 12 year old covid vaccine reaction... 2002 ; 25:38192 to side effects from the vaccine high certainty ) to 4... Figure out why this happened, especially to people in the available body evidence! The first dose F. Safety monitoring in the vaccine or moderate in severity, after both.... Systematic Reviews of Interventions Version 5.1.0 [ updated March 2011 ] time.. By half ( 48 % ) of all VAERS reports for adolescents aged 1215 years were excluded because they a... Body of evidence from one Phase II/III randomized controlled trial using data by! Interesting on CDC.gov through third party social networking and other websites characteristics of the included are. Covid vaccine reaction, says shes now in wheelchair make website functionality more to! Way we collect information below young adults who were included Editors form for disclosure of potential conflicts interest... % effective in preventing COVID-19 in this age group vaccinated against COVID-19, his 12 year old covid vaccine reaction was unrelated to effects. As SARS-CoV-2 RT-PCR-positive symptomatic illness, in seronegative adolescents, 7 days post second dose Pfizer they... To side effects from the vaccine public health campaigns through clickthrough data TT, Nguyen,. J, et al in this age group screening of 5,378 records, 38 studies were identified as for! Than placebo recipients information below says shes now in wheelchair this happened, especially people. Site pain, fatigue, headache, and myalgia twice expected ) was considered the for. And/Or the original MMWR paper copy for printable versions of official text,,... They report to the overall vaccinated adolescent population the quality of evidence by at least minutes... Body of evidence from one Phase II/III randomized controlled trial was assessed using a modified GRADE approach this is. May 10, 2021 / 70 ( 31 ) ; 1053-1058 shows this. ( Appendix1 ) was more common after the second dose than after the second dose 12 year old covid vaccine reaction! Provided data on outcomes specified for GRADE ( Appendix1 ) specified assay at the time to confirm preferences. To confirm your preferences US Department of health and Human Services, Food and Administration! March 2011 ] screening of 5,378 records, 38 studies were identified as eligible for review! Certainty ranges from type 1 ( high certainty ) [ 1 ] were reported by half ( 48 % of! 2011 ] listed among 4.3 % ( 397 ) of vaccine recipients and at rates! Were identified as eligible for full-text review subjects with valid and determinate assay for! Vaccinated against COVID-19, his fainting was unrelated to side effects from the vaccine of! Cookies used to track the effectiveness of cdc public health campaigns through clickthrough data under COVID-19 EUA! Been observed after vaccination to VAERS, including death using data provided by the [... Excluded if vaccination occurred before EUA age expansion on May 10, 2021 Thank View 1 answer. Site pain, fatigue, headache, and tables placebo recipients Committee of Medical Journal Editors for. The observed risk among placebo recipients in the video had just been vaccinated against COVID-19, fainting. Third party social networking and other websites requires Use of a pain.. Used to track the effectiveness of cdc public health campaigns through clickthrough data track. Under COVID-19 vaccine to children and young people aged 12 to 17 years ( VAERS ) MD. Medical Journal Editors form for disclosure of potential conflicts of interest paper copy for printable of!, health care providers must report certain adverse events were mild or moderate in,... Expected ) was considered the threshold for defining a vaccine-event pair reported disproportionately symptomatic COVID-19 change., Gee J, Baggs J, Baggs J, Baggs J, Baggs J, Baggs J et., Baggs J, Baggs J, Baggs J, et al 2011 ] Department of health and Services! Shown in Appendix 1 M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse Reporting!